Watch BBNX. Know when insiders buy.
One email the day a filing lands. Free.
Work order
41
WATCH · insiders 27, shorts 54
Insiders, 90 days
−$829K
net selling · 0 buys, 6 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $873.7MP/E —DIV YIELD —FCF YIELD -7.03%REV TTM $119M +52.5%NET INCOME −$73MNET CASH —52W 8.86 – 31.99SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $32M | +37.8% | 59.0% | −$25.6M | −$23.4M | — | -0.53 | −$14.6M | $1M | −$15.7M | Jul 29 |
| Q1 2026 · Mar 31 | $27.6M | +56.6% | 59.5% | −$24.3M | −$21.9M | — | -0.49 | −$23.8M | $1.4M | −$25.2M | Apr 21 |
| Q4 2025 · Dec 31derived | $32.1M | +57.1% | 59.0% | −$16.1M | −$13.5M | — | -0.29 | −$8.6M | $1.9M | −$10.5M | Feb 24 |
| Q3 2025 · Sep 30 | $27.3M | +63.1% | 55.5% | −$17M | −$14.2M | — | -0.33 | −$8.7M | $1.3M | −$10M | Oct 28 |
| Q2 2025 · Jun 30 | $23.2M | +54.4% | 53.8% | −$19.9M | −$16.9M | — | -0.39 | −$13.6M | $1.8M | −$15.4M | Jul 29 |
| Q1 2025 · Mar 31 | $17.6M | +36.4% | 50.9% | −$18.6M | −$28.7M | — | -0.93 | −$20M | $333K | −$20.3M | Apr 21 |
| Q4 2024 · Dec 31derived | $20.4M | — | 57.2% | −$13M | −$18.1M | — | -2.74 | −$14.3M | $561K | −$14.8M | Feb 24 |
| Q3 2024 · Sep 30 | $16.7M | — | 53.4% | −$11M | −$9.7M | — | -1.46 | −$9.6M | $1.9M | −$11.5M | Oct 28 |
| Q2 2024 · Jun 30 | $15M | — | 53.7% | −$11.8M | −$14.5M | — | -2.37 | −$12.2M | $507K | −$12.7M | Jul 29 |
| Q1 2024 · Mar 31 | $12.9M | — | 55.7% | −$9.5M | −$12.4M | — | -2.07 | −$12.1M | $406K | −$12.6M | May 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $100.3M | 55.4% | −$71.7M | −$73.2M | -73.0% | -1.81 | −$50.9M | $5.3M | −$56.2M | — | — |
| FY2024 · to Dec 31 | $65.1M | 55.1% | −$45.3M | −$54.8M | -84.1% | -8.60 | −$48.3M | $3.4M | −$51.7M | — | — |
| FY2023 · to Dec 31 | $12M | 52.6% | −$35.9M | −$44.1M | -367.6% | -8.31 | −$32.4M | $402K | −$32.8M | — | — |
Every number comes from Beta Bionics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.